URGN.NASDAQUrogen Pharma LTD

SCHEDULE: TD Bank Discloses 6.9% Stake in UroGen Pharma

Sentiment:

Beneficial Ownership Report

📋All filings for Urogen Pharma LTD
🔒Login to Follow

The Toronto-Dominion Bank has reported a 6.9% beneficial ownership stake in UroGen Pharma Ltd., holding 3,190,510 ordinary shares.

Summary

  • The Toronto-Dominion Bank has filed a Schedule 13G, disclosing beneficial ownership of 3,190,510 ordinary shares of UroGen Pharma Ltd.
  • This ownership represents 6.9% of UroGen Pharma Ltd.'s outstanding ordinary shares.
  • The Toronto-Dominion Bank holds sole voting power and sole dispositive power over all 3,190,510 shares.
  • The event requiring this filing occurred on September 30, 2025.
  • The beneficial ownership was transferred to The Toronto-Dominion Bank from Cowen Financial Products LLC, an affiliated entity, between the event date and the filing date.

Sentiment

Score: 7

Explanation: The disclosure of a significant stake by a major financial institution like The Toronto-Dominion Bank is generally viewed positively, indicating institutional confidence in the issuer.

Positives

  • A significant institutional investor, The Toronto-Dominion Bank, has taken a 6.9% stake in UroGen Pharma Ltd., which can be interpreted as a vote of confidence in the company's prospects.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a significant institutional investment by a major financial institution, The Toronto-Dominion Bank, in UroGen Pharma Ltd. Such filings are common disclosures when an entity acquires more than 5% beneficial ownership of a public company's stock, signaling institutional interest and potentially validating the company's market position within its sector.

Related Party Transactions

  • The beneficial ownership of the securities was transferred to The Toronto-Dominion Bank from Cowen Financial Products LLC, an affiliated entity, between the event date and the filing date.

Stakeholder Impact

  • Shareholders may view the significant stake taken by The Toronto-Dominion Bank as a positive signal, potentially increasing investor confidence and market interest in UroGen Pharma Ltd.

Key Dates

DateDescription
09/30/2025Date of event which required the filing of this statement (when the beneficial ownership threshold was crossed).
11/13/2025Date the Schedule 13G statement was signed by The Toronto-Dominion Bank.

Recommendation

hold

The filing indicates a significant institutional stake, which can be a positive signal. However, as this is purely an ownership disclosure and not a performance report or strategic update, a 'hold' recommendation is appropriate, suggesting investors monitor further developments and company performance rather than making immediate buy/sell decisions based solely on this filing.

Keywords

UroGen Pharma Ltd., The Toronto-Dominion Bank, TD Bank, Beneficial Ownership, Schedule 13G, Institutional Investment, Ordinary Shares, M96088105

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.